Antiemetic control: Toward a new standard of care for emetogenic chemotherapy

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 4, 2009, Pages 629-644

  Navari, Rudolph M ^a,b  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiemetics; Chemotherapy induced nausea and vomiting; Neurokinin 1 receptor antagonists; Serotonin receptor antagonists

Indexed keywords

ANTHRACYCLINE; APREPITANT; AZASETRON; BLEOMYCIN; BUTYROPHENONE; CANNABINOID; CARBOPLATIN; CASOPITANT; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; FOSAPREPITANT; GABAPENTIN; GRANISETRON; IRINOTECAN; METOCLOPRAMIDE; MITOXANTRONE; OLANZAPINE; ONDANSETRON; PALONOSETRON; PHENOTHIAZINE; RAMOSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON; UNINDEXED DRUG; VINCA ALKALOID; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE; MORPHOLINE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ACUTE DISEASE; ANTICIPATORY NAUSEA AND VOMITING; ANTIEMETIC ACTIVITY; BINDING AFFINITY; BONE MARROW TRANSPLANTATION; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE CONTROL; DISORIENTATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HALF LIFE TIME; HEADACHE; HUMAN; INSOMNIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PATIENT CARE; POSTOPERATIVE NAUSEA AND VOMITING; PROPHYLAXIS; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; NAUSEA; PHASE 3 CLINICAL TRIAL; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; ISOQUINOLINES; MORPHOLINES; NAUSEA; PIPERAZINES; PIPERIDINES; QUINUCLIDINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 65649136950     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902731894     Document Type: Review

References (94)

1. NCCN Clinical practice guidelines in oncology; v.2.2006: Antiemesis. National Comprehensive Cancer Network (NCCN), 2006. Available from: http://www.nccn.org/professionals/physician-gls/PDF/antiemesis. pdf. [Last accessed 22 November 2006]. •• Antiemetic guidelines.
2. Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15(5):497-503 (Pubitemid 46570778)
3. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-4478 (Pubitemid 46630986)
4. Gralla RJ, de Wit R, Herrstedt, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5-HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 2005;104:864-868 (Pubitemid 41113689)
5. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006;4(2 suppl 1):3-8 (Pubitemid 43338178)
6. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 2005;13:80-84 (Pubitemid 40558162)
7. Guyton AC. Physiology of gastrointestinal disorders. In: Guyton AC, Hall JE, textbook of medical physiology. Philadelphia: Elsevier Saunders, 2006
8. Baker PD, Morzorati SL, Ellett ML. The pathophysiology of chemotherapy-induced nausea and vomiting. Gastroenterol Nurs 2005;28:469-480
9. Borison HL, McCarthy LE. Neuropharmacology of chemotherapy-induced emesis. Drugs 1983;25:8-17 (Pubitemid 13195443)
10. Yates BJ, Grelot L, Kerman IA, et al. Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Physiol 1994;267:R974-83 (Pubitemid 2158879)
11. Navari RM. Review of updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Commun Oncol 2007;4(suppl 1):3-11 •• Antiemetic guidelines.
12. Roila F, Hesketh PJ, Herrstedt J. Antiemetic subcommittee of the multinational association of supportive care in cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-28
13. Kris MG, Hesketh PJ, Somerfield MR, et al. American society of clinical oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947 •• Antiemetic guidelines. (Pubitemid 46630595)
14. Hesketh PJ, Navari RM, Grote T, et al. Double blind randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242-2249 (Pubitemid 26264874)
15. Navari RM, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-1248
16. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a selective, 5-hydroxytryptamine receptor antagonist, for the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol 1994;12:2204-2210 (Pubitemid 24356040)
17. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995;13:1036-1043
18. Sanger GJ. The involvement of the 5-HT3 receptors in visceral function. In: Central and peripheral 5-HT¬3 receptors. London: Academic Press, 1992
19. Roila F, Warr D, Clark-Snow R, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005;13(2):104-108 (Pubitemid 40558165)
20. Latreille J, Pater J, Johnston D, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 1998;16:1174-1178 (Pubitemid 28108755)
21. Navari RM, Madajcwicz S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995;13:2408-2416
22. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000;342:1554-1559
23. Geling O, Eichler H. Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-1294 • Review of delayed nausea. (Pubitemid 46202287)
24. Hickok JT, Roscoe JA, Morrow GR, et al. 5-HT3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 2005;6:765-772 (Pubitemid 41430717)
25. Rudd JA, Naylor RJ. Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 1994;33:1607-1608
26. Andrews PLR. 5-HT3 receptor antagonists and antiemesis. In: 5-Hydroxytryptamine-3 receptor antagonists. Boca Raton/London: CRC Press, 1994
27. Hesketh PJ. New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer 2004;12:550-554 (Pubitemid 39062545)
28. Mantovani G, Maccio A, Aslexandro B, et al. Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer; a randomized controlled trial. Cancer 1996;77:941-948 (Pubitemid 26061290)
29. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: Two new agents. J Support Oncol 2003;1:89-103 • Antiemetic review.
30. Simpson K, Spencer CM, McClellan KJ. Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000;59:1297-1315 (Pubitemid 30410146)
31. Kimura E, Niimi E, Watanabe A, et al. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 1996;23:477-481 (Pubitemid 26119996)
32. Taguchi T, Tsukamoto F, Watanabe T, et al. Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 1999;26:1163-1170
33. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18:163-173 (Pubitemid 30118410)
34. Perez EA, Navari RM, Kaplan HG, et al. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer 1997;5:31-37 (Pubitemid 27163465)
35. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother 2003;37:1276-1286 (Pubitemid 37040221)
36. Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5 hydroxytryptamine-3 antiemetics. Cancer 2003;97:2880-2886
37. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-2482 • Palonosetron data.
38. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577 • Palonosetron data. (Pubitemid 37304615)
39. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-1449 • Palonosetron data. (Pubitemid 44400384)
40. Cartmell AD, Ferguson S, Yanagihara R, et al. Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT3 receptor antagonist. Proc Am Soc Clin Oncol 2003; [abstract 3041]
41. Kris MG. Why do we need another antiemetic? J Clin Oncol 2003;21:4077-4080
42. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60:533-546 (Pubitemid 30780109)
43. Fasth KJ, Bergstrom M, Kilpatrick G. Brain uptake and receptor binding of two C11 labeled selective high affinity NK-1 antagonists, GR 203040 and GR 205171. J Labeled Comp Radiopharm 1997;40:665-667
44. Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK-1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996;35:1121-1129 (Pubitemid 27008187)
45. Minami M, Endo T, Kikuchi K, et al. Antiemetic effects of sendide, a peptide tachykinin NK-1 receptor antagonist, in the ferret. Eur J Pharmacol 1998;363:49-55 (Pubitemid 29056216)
46. Minami M, Endo T, Yokoda H, et al. Effects of CP-99,994, a tachykinin NK-1 receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK-1 and 5-HT3 receptors. Eur J Pharmacol 2001;428:215-220
47. Tattersall FD, Rycroft W, Cumberbatch M, et al. The novel NK-1 receptor antagonist MK-869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 2000;39:652-663
48. Kris MG, Radford JE, Pizzo BA, et al. Use of a NK-1 receptor antagonist to prevent delayed emesis after cisplatin (letter). J Natl Cancer Inst 1997;89:817-818 (Pubitemid 27242284)
49. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin-1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999;17:338-343 (Pubitemid 29022412)
50. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokin-1 receptor antagonist. N Engl J Med 1999;340:190-195 (Pubitemid 29063215)
51. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001;37:835-842
52. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-1767 (Pubitemid 32230878)
53. Van Belle S, Liechinitser M, Navari RM, et al. Prevention of cisplatin- induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002;94:3032-3041 (Pubitemid 34547705)
54. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK-1 antagonist Aprepitant for chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-2300
55. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin-The Aprepitant protocol 052 study group. J Clin Oncol 2003;21:4112-4119 • Aprepitant data. (Pubitemid 46606178)
56. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin-1 receptor antagonist Aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 2003;97:3090-3098 • Aprepitant data.
57. de Wit R, Herrsted J, Rapoport BL, et al. Addition of the oral NK-1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-4111 (Pubitemid 46606177)
58. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17(6):1000-1006 (Pubitemid 43778994)
59. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-2830 • Aprepitant data. (Pubitemid 46179473)
60. Navari RM. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and antinausea activities. Curr Opin Investig Drugs 2008;9:774-785 • Review of casopitant. (Pubitemid 351950873)
61. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK-1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-410 (Pubitemid 38121278)
62. Navari RM. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2004;4(5):715-724 (Pubitemid 39359859)
63. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004;64:777-794 (Pubitemid 38471378)
64. Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 2007;16:1977-85 • Review of fosaprepitant.
65. Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007;47:834-840
66. Arpornwirat W. Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). [abstract 8512]. Proc Am Soc Clin Oncol 2006;4:471s
67. Rolski J. Randomized phase II trial of the neurokinin-1 receptor antagonist (NK1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). [abstract 8513]. Proc Am Soc Clin Oncol 2006;24:471s
68. Grunberg SM, Aziz Z, Shaharyar A, et al. Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). [abstract 9540]. Proc Am Soc Clin Oncol 2008;26:471s • Casopitant data.
69. Strausz J, Rolski J, Aziz Z, et al. Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC).[abstract 20585]. Proc Am Soc Clin Oncol 2008;26:731s • Casopitant data.
70. Post-operative nausea and vomiting study in female patients. Available from: www.clinicaltrials.gov [Last accessed 13 May 2008]
71. A study of iv casopitant for the prevention of chemotherapy-induced nausea and vomiting. Available from: www.clinicaltrials.gov [Last accessed 13 May 2008]
72. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994;12:596-600 (Pubitemid 24079904)
73. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1-5
74. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer 1995;3:307-312
75. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000;18:3409-3422 (Pubitemid 30821918)
76. The Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998;16:2937-2942
77. The Italian Group for Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004;22:725-729 [Erratum, J Clin Oncol 2004;22:2038.]
78. Bymaster FP, Calligaro D, Falcone J, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96 (Pubitemid 26053226)
79. Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine. Eur J Pharmacol 2001;430:341-349
80. Allison DB, Casey DE. Antipsychotic-associated weight gain: A review of the literature. J Clin Psychiatry 2001;62:22-31 (Pubitemid 32402182)
81. Hale AS. Olanzapine. Br J Hosp Med 1997;58:443-445
82. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-443 (Pubitemid 29407221)
83. Passik SD, Navari RM, Loehrer PJ, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest 2004;22:383-388 (Pubitemid 39310908)
84. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 2005;13:529-534 • Olanzapine data.
85. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 2007;15:1285-1291 • Olanzapine data.
86. Guttuso T, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 2003;361:1703-1705 (Pubitemid 36577445)
87. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310:329-332
88. Martin BR, Wiley JL. Mechanism of action of cannabinoids; how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2004;2:305-316 (Pubitemid 39409773)
89. Slatin MD. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 2007;5(suppl 3):1-9
90. Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002;10:517-518 (Pubitemid 36061646)
91. Navari RM. Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw 2007;5:51-59 • Multiple-day chemotherapy.
92. Einhorn LH, Brames ML, Dreicer R, et al. Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007;15:1293-1300 (Pubitemid 47583451)
93. Grunberg SM, Deuson R, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer 2004;100:2261-2268 (Pubitemid 38580348)
94. Fabi A, Barduagni M, Lauro S, et al. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 2003;11:156-161 (Pubitemid 36733809)